187 related articles for article (PubMed ID: 17583416)
1. Overall survival in the intervention arm of a randomized controlled screening trial for prostate cancer compared with a clinically diagnosed cohort.
Vis AN; Roemeling S; Reedijk AM; Otto SJ; Schröder FH
Eur Urol; 2008 Jan; 53(1):91-8. PubMed ID: 17583416
[TBL] [Abstract][Full Text] [Related]
2. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
3. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
Roobol MJ; Grenabo A; Schröder FH; Hugosson J
J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
[TBL] [Abstract][Full Text] [Related]
4. Overall and disease-specific survival of patients with screen-detected prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam.
de Vries SH; Postma R; Raaijmakers R; Roemeling S; Otto S; de Koning HJ; Schröder FH
Eur Urol; 2007 Feb; 51(2):366-74; discussion 374. PubMed ID: 16930812
[TBL] [Abstract][Full Text] [Related]
5. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
Schröder FH; Bangma CH; Roobol MJ
Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
[TBL] [Abstract][Full Text] [Related]
6. Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Roemeling S; Roobol MJ; Gosselaar C; Schröder FH
Prostate; 2006 Jul; 66(10):1076-81. PubMed ID: 16637077
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial.
Aus G; Bergdahl S; Lodding P; Lilja H; Hugosson J
Eur Urol; 2007 Mar; 51(3):659-64. PubMed ID: 16934392
[TBL] [Abstract][Full Text] [Related]
8. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.
Postma R; Schröder FH; van Leenders GJ; Hoedemaeker RF; Vis AN; Roobol MJ; van der Kwast TH
Eur Urol; 2007 Jul; 52(1):89-97. PubMed ID: 17257742
[TBL] [Abstract][Full Text] [Related]
9. Tumor characteristics in a population-based prostate cancer screening trial with prostate-specific antigen.
Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
Clin Cancer Res; 2003 Jul; 9(7):2435-9. PubMed ID: 12855615
[TBL] [Abstract][Full Text] [Related]
10. Metastatic disease of screen-detected prostate cancer : characteristics at diagnosis.
Roemeling S; Kranse R; Vis AN; Gosselaar C; van der Kwast TH; Schröder FH
Cancer; 2006 Dec; 107(12):2779-85. PubMed ID: 17109445
[TBL] [Abstract][Full Text] [Related]
11. Dihydrotestosterone levels and survival in screening-detected prostate cancer: a 15-yr follow-up study.
Kjellman A; Akre O; Norming U; Törnblom M; Gustafsson O
Eur Urol; 2008 Jan; 53(1):106-11. PubMed ID: 17482753
[TBL] [Abstract][Full Text] [Related]
12. Survival in prostate carcinoma--outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden.
Aus G; Robinson D; Rosell J; Sandblom G; Varenhorst E;
Cancer; 2005 Mar; 103(5):943-51. PubMed ID: 15651057
[TBL] [Abstract][Full Text] [Related]
13. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam.
van der Cruijsen-Koeter IW; Vis AN; Roobol MJ; Wildhagen MF; de Koning HJ; van der Kwast TH; Schröder FH
J Urol; 2005 Jul; 174(1):121-5. PubMed ID: 15947595
[TBL] [Abstract][Full Text] [Related]
14. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome.
Roemeling S; Roobol MJ; de Vries SH; Wolters T; Gosselaar C; van Leenders GJ; Schröder FH
Eur Urol; 2007 May; 51(5):1244-50; discussion 1251. PubMed ID: 17161520
[TBL] [Abstract][Full Text] [Related]
15. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation.
Connolly D; Black A; Gavin A; Keane PF; Murray LJ
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):271-8. PubMed ID: 18250343
[TBL] [Abstract][Full Text] [Related]
16. Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: self-selection bias?
Otto SJ; Schröder FH; de Koning HJ
J Med Screen; 2004; 11(2):89-92. PubMed ID: 15153324
[TBL] [Abstract][Full Text] [Related]
17. Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates.
Feuer EJ; Mariotto A; Merrill R
Cancer; 2002 Aug; 95(4):870-80. PubMed ID: 12209732
[TBL] [Abstract][Full Text] [Related]
18. 15-year followup of a population based prostate cancer screening study.
Kjellman A; Akre O; Norming U; Törnblom M; Gustafsson O
J Urol; 2009 Apr; 181(4):1615-21; discussion 1621. PubMed ID: 19233435
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis.
Brenner H; Arndt V
J Clin Oncol; 2005 Jan; 23(3):441-7. PubMed ID: 15572727
[TBL] [Abstract][Full Text] [Related]
20. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden.
Sandblom G; Varenhorst E; Löfman O; Rosell J; Carlsson P
Eur Urol; 2004 Dec; 46(6):717-23; discussion 724. PubMed ID: 15548438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
